```
=> d his

     (FILE 'HOME' ENTERED AT 11:30:04 ON 22 JUN 2004)

     FILE 'REGISTRY' ENTERED AT 11:30:17 ON 22 JUN 2004
               E DICLOFENAC/CN
L1             1 S E3

     FILE 'CAPLUS' ENTERED AT 11:51:54 ON 22 JUN 2004
L2          4723 S PRIDINOL OR  511-45-5/RN OR NONPLESIN OR NSC(W)(23016 OR 4037
L3          2127 S 169590-42-5/RN OR  CELECOXIB OR CELEBREX OR 123653-11-2/RN OR
L4             1 S L2(L)L3

     FILE 'USPATFULL' ENTERED AT 12:06:07 ON 22 JUN 2004

     FILE 'EUROPATFULL, FRFULL, PATDPAFULL, PCTFULL, RDISCLOSURE, USPATFULL,
     USPAT2' ENTERED AT 12:06:13 ON 22 JUN 2004
               E FAOUR J/IN
L5            43 S E4

     FILE 'USPATFULL, USPAT2' ENTERED AT 12:08:43 ON 22 JUN 2004
L6             2 S L5 AND L4
```

own pct

Not prior art/NO OOP

```
=> s Pridinol or  511-45-5/rn or Nonplesin or NSC(w)(23016 or 403797) or parks or
122852-42-0/rn or  Alosetron or GR(w)68755 or  1134-47-0/rn or  Baclofen or Baclon
            39 PRIDINOL
            59 511-45-5
             2 511-45-5D
            57 511-45-5/RN
                 (511-45-5 (NOTL) 511-45-5D )
             0 NONPLESIN
          3232 NSC
           164 NSCS
          3331 NSC
                 (NSC OR NSCS)
             4 23016
             0 403797
             0 NSC(W)(23016 OR 403797)
          1001 PARKS
           104 122852-42-0
             2 122852-42-0D
           103 122852-42-0/RN
                 (122852-42-0 (NOTL) 122852-42-0D )
           110 ALOSETRON
         51322 GR
          1620 GRS
         52409 GR
                 (GR OR GRS)
             3 68755
             2 GR(W)68755
          1843 1134-47-0
            42 1134-47-0D
          1816 1134-47-0/RN
                 (1134-47-0 (NOTL) 1134-47-0D )
          3395 BACLOFEN
             2 BACLOFENS
          3396 BACLOFEN
                 (BACLOFEN OR BACLOFENS)
             0 BACLON
L2        4723 PRIDINOL OR  511-45-5/RN OR NONPLESIN OR NSC(W)(23016 OR 403797)
                OR PARKS OR  122852-42-0/RN OR  ALOSETRON OR GR(W)68755 OR
               1134-47-0/RN OR  BACLOFEN OR BACLON

=> s 169590-42-5/rn or
MISSING TERM AFTER 0-42-5/RN OR
Operators must be followed by a search term, L-number, or query name.

=> s 169590-42-5/rn or  Celecoxib or Celebrex or 123653-11-2/rn or  NS(w)398 or
88149-94-4/rn or DuP(w)697
           966 169590-42-5
            23 169590-42-5D
           956 169590-42-5/RN
                 (169590-42-5 (NOTL) 169590-42-5D )
          1116 CELECOXIB
            80 CELEBREX
           439 123653-11-2
             6 123653-11-2D
           438 123653-11-2/RN
                 (123653-11-2 (NOTL) 123653-11-2D )
         56288 NS
            14 NSES
         56301 NS
                 (NS OR NSES)
          6334 398
           875 NS(W)398
            78 88149-94-4
```

```
             1 88149-94-4D
            77 88149-94-4/RN
                 (88149-94-4 (NOTL) 88149-94-4D )
          1015 DUP
          2513 697
            72 DUP(W)697
L3        2127 169590-42-5/RN OR  CELECOXIB OR CELEBREX OR 123653-11-2/RN OR
               NS(W)398 OR 88149-94-4/RN OR DUP(W)697

=> s l2(l)l3
L4             1 L2(L)L3

=> d ibib abs kwic

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER:         2002:574855  CAPLUS
DOCUMENT NUMBER:          137:129887
TITLE:                    Pharmaceutical compositions containing a COX-II
                          inhibitor and a muscle relaxant
INVENTOR(S):              Faour, Joaquina; Vergez, Juan A.
PATENT ASSIGNEE(S):       Osmotica Costa Rica Sociedad Anonima, Costa Rica
SOURCE:                   PCT Int. Appl., 64 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 Spanish
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
     WO 2002058620      A2   20020801       WO 2002-CR1      20020125
     WO 2002058620      A3   20021212
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
             PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
             UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
             TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
             CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     EP 1362585         A2   20031119       EP 2002-711756   20020125
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRIORITY APPLN. INFO.:                  US 2001-770901   A  20010126
                                        WO 2002-CR1      W  20020125
```

Applicant own PCT

AB The invention relates to a pharmaceutical composition and a dosage form that combines a COX-II inhibitor and a muscle relaxant. The pharmaceutical composition is used to treat pain and disorders and symptoms associated with pain.

The combination provides an improved therapeutic response compared to all other single drugs. The pharmaceutical composition can be administered in any dosage form. The muscle relaxant may be alcuronium, **alosetron**, aminophylline, **baclofen**, carisoprodol, etc. The COX-II inhibitor may be rofecoxib, **celecoxib**, flosulide, **NS-398**, etc.

AB The invention relates to a pharmaceutical composition and a dosage form that combines a COX-II inhibitor and a muscle relaxant. The pharmaceutical composition is used to treat pain and disorders and symptoms associated with pain.

The combination provides an improved therapeutic response compared to all other single drugs. The pharmaceutical composition can be administered in any dosage form. The muscle relaxant may be alcuronium, **alosetron**,

FILE 'USPATFULL' ENTERED AT 12:08:43 ON 22 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 12:08:43 ON 22 JUN 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l5 and l4
L6 2 L5 AND L4

=> d ibib abs 1-2

L6 ANSWER 1 OF 2 USPATFULL on STN
ACCESSION NUMBER: 2002:242824 USPATFULL
TITLE: Combined diffusion / osmotic pumping drug delivery system
INVENTOR(S): **Faour, Joaquina**, Buenos Aires, ARGENTINA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132005	A1	20020919
	US 6753011	B2	20040622
APPLICATION INFO.:	US 2002-47915	A1	20020115 (10)

NO ODP

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-483282, filed on 14 Jan 2000, GRANTED, Pat. No. US 6352721

	NUMBER	DATE
PRIORITY INFORMATION:	WO 2001-US562	20010108

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: INNOVAR, LLC, P O BOX 250647, PLANO, TX, 75025
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 1705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Delivery devices capable of delivering one or more active substances by diffusion through plural micropores in the membrane (4) or by osmotic pumping through one or more preformed passageways (5) in the membrane are provided. The device (1) has an about centrally located expandable core (2) completely surrounded by an active substance-containing layer (3), which is completely surrounded by the membrane. The device is capable of delivering insoluble, slightly soluble, sparingly soluble and very soluble active substances to an environment of use. The preferred delivery rate is zero order. The device can deliver an active substance for a period of about 12-24 hours.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 2 USPAT2 on STN
ACCESSION NUMBER: 2002:242824 USPAT2
TITLE: Combined diffusion/osmotic pumping drug delivery system
INVENTOR(S): **Faour, Joaquina**, Buenos Aires, ARGENTINA
PATENT ASSIGNEE(S): Osmotica Corp, Tortola, VIRGIN ISLANDS (BRITISH) (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6753011	B2	20040622
APPLICATION INFO.:	US 2002-47915		20020115 (10)

NO ODP

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 2000-483282, filed on 14 Jan 2000, now patented, Pat. No. US 6352721
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED

PRIMARY EXAMINER: Spear, James M.
LEGAL REPRESENTATIVE: Matos, Rick, Innovar, L.L.C.
NUMBER OF CLAIMS: 30
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1683
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Delivery devices capable of delivering one or more active substances by diffusion through plural micropores in the membrane (4) or by osmotic pumping through one or more preformed passageways (5) in the membrane are provided. The device (1) has an about centrally located expandable core (2) completely surrounded by an active substance-containing layer (3), which is completely surrounded by the membrane. The device is capable of delivering insoluble, slightly soluble, sparingly soluble and very soluble active substances to an environment of use. The preferred delivery rate is zero order. The device can deliver an active substance for a period of about 12-24 hours.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d kwic

L6 ANSWER 1 OF 2 USPATFULL on STN
IN **Faour, Joaquina**, Buenos Aires, ARGENTINA
DETD . . . Representative anti-inflammatory and analgesic drugs include cortisone, hydrocortisone, prednisone, prednisolone, betamethasone, dexamethasone and fluorocortisone; cyclooxygenase II inhibitors such as rofecoxib, **celecoxib**, flosulide, **NS-398**, **DUP-697**, meloxicam, 6-methoxy-2-naphthylacetic acid, nabumetone, etodolac, nimesulide, SC-5766, SC-58215, T-614; salicylates such as salicylic acid, aspirin and diflunisal; pyrazolon derivates such. . .
DETD [0102] Representative muscle relaxants and antispasmodic agents include alcuronium, **alosetron**, aminophylline, **baclofen**, carisoprodol, chlorphenesin, chlorphenesin carbamate, chlorzoxazone, chlormezanone, cyclobenzaprine, dantrolene, decamethonium, diazepam, dyphylline, eperisione, ethaverine, gallamine triethiodide, hexafluorenium, mephenesin, metaxalone, methocarbamol, metocurine iodide, orphenadrine, pancuronium, papaverine, pipecuronium, **pridinol**, succinylcholine, theophylline, tizanidine, tolperisone, tubocurarine, vecuronium, idrocilamide, ligustilide, cnidilide, senkyunolide, **baclofen**, trihexylphenidyl, **pridinol**, and biperiden.

=> d clm

L6 ANSWER 1 OF 2 USPATFULL on STN
CLM What is claimed is:
1. A device for the controlled delivery of at least one active agent to an environment of use, wherein the device comprises: a core expandable in a fluid from the environment of use, the core being approximately centrally located in the device; a layer comprising at least one first active agent, wherein the layer is in contact with and surrounds the core; and a membrane in contact with and surrounding the layer and comprising at least one preformed passageway for delivery of the at least one active agent by osmotic pumping and plural micropores for delivery of the at least one active agent by diffusion, and the membrane further comprising one or more cellulose esters, one or more poly(methacrylate) copolymer salts and one or more plasticizers, wherein the membrane permits delivery of the at least one active substance through a combination of diffusion and osmotic pumping.

2. A device according to claim 1 further comprising a drug-containing coat external to the membrane and comprising a second active agent, wherein the drug-containing coat provides an immediate, rapid, controlled or delayed release of the second active agent and the external coat surrounds at least a portion of the membrane.

3. A device according to claim 2, wherein the first and second active agents are different and are independently selected at each occurrence from the group consisting of an antibiotic agent, antihistamine agent, decongestant, anti-inflammatory agent, antiparasitic agent, antiviral agent, local anesthetic, antifungal agent, amoebicidal agent, trichomonocidal agent, analgesic agent, anti-arthritic agent, anti-asthmatic agent, anticoagulant agent, anticonvulsant agent, antidepressant agent, antidiabetic agent, antineoplastic agent, anti-psychotic agent, neuroleptic agent, antihypertensive agent, hypnotic agent, sedative agent, anxiolytic energizer agent, antiparkinson agent, muscle relaxant agent, antimalarial agent, hormonal agent, contraceptive agent, sympathomimetic agent, hypoglycemic agent, antilipemic agent, ophthalmic agent, electrolytic agent, diagnostic agent, prokinetic agent, gastric acid secretion inhibitor agent, anti-ulcerant agent, anti-flatulent agent, anti-incontinence agent, and cardiovascular agent.

4. A device according to claim 3, wherein the first active agent is a prokinetic agent and the second active agent is a gastric acid secretion inhibitor agent.

5. A device according to claim 3, wherein the first active agent is a decongestant and the second active agent is an antihistamine.

6. A device according to claim 3, wherein the first active agent is a first anti-incontinence agent and the second active agent is a different second anti-incontinence agent.

7. A device according to claim 6, wherein the anti-incontinence agents are selected from the group consisting of oxybutynin, tolterodine and darifenacin.

8. A device according to claim 3, wherein the first active agent is a first antihypertensive agent and the second active agent is a different second antihypertensive agent.

9. A device according to claim 8, wherein the antihypertensive agents are selected from the group consisting of a calcium channel blocker agent, an angiotensin converting enzyme inhibitor agent, a diuretic agent and a beta-adrenergic antagonist agent.

10. A device according to claim 3, wherein the first active agent is an antidepressant agent and the second active agent is an anti-psychotic agent.

11. A device according to claim 3, wherein the first active agent is a first analgesic or anti-inflammatory agent, and the second active agent is a different second analgesic or anti-inflammatory agent.

12. A device according to claim 11, wherein the analgesic and anti-inflammatory agents are selected from the group consisting of an non-steroidal anti-inflammatory agent, a steroidal anti-inflammatory agent, an opioid receptor agonist agent, and a selective or specific COX-II inhibitor agent.

13. A device according to claim 3, wherein the first active agent is an antiviral agent and the second active agent is an antihistamine agent.

14. A device according to claim 3, wherein the first active agent is a muscle relaxant agent and the second active agent is an anti-inflammatory or analgesic agent.

15. A device according to claim 14, wherein the first active agent is pridinol and the second active agent is a selective or specific COX-II inhibitor agent.

16. A device according to claim 2, wherein the first and second active agents are the same and are selected from the group consisting of an antibiotic agent, antihistamine agent, decongestant, anti-inflammatory agent, antiparasitic agent, antiviral agent, local anesthetic, antifungal agent, amoebicidal agent, trichomonocidal agent, analgesic agent, anti-arthritic agent, anti-asthmatic agent, anticoagulant agent, anticonvulsant agent, antidepressant agent, antidiabetic agent, antineoplastic agent, anti-psychotic agent, neuroleptic agent, antihypertensive agent, hypnotic agent, sedative agent, anxiolytic energizer agent, antiparkinson agent, muscle relaxant agent, antimalarial agent, hormonal agent, contraceptive agent, sympathomimetic agent, hypoglycemic agent, antilipemic agent, ophthalmic agent, electrolytic agent, diagnostic agent, prokinetic agent, gastric acid secretion inhibitor agent, anti-ulcerant agent, anti-flatulent agent, anti-incontinence agent, and cardiovascular agent.

17. A device according to claim 1, wherein the membrane comprises about 1 to 99 weight percent of one or more cellulose esters, about 84 to 0.5 weight percent of one or more poly(methacrylate) copolymer salts and about 15 to 0.5 weight percent of one or more plasticizers.

18. A device according to claim 1, wherein the cellulose ester is selected form the group consisting of cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate and combinations thereof.

19. A device according to claim 1, wherein the poly(methacrylate) copolymer salt is poly(ammonium methacrylate) copolymer.

20. A device according to claim 1, wherein the plasticizer is selected from the group consisting of acetyl triethyl citrate, acetyl tributyl citrate, triethyl citrate, acetylated monoglycerides, glycerol, poly(ethylene glycol), triacetin, propylene glycol, dibutyl phthalate, diethyl phthalate, dipropyl phthalate, dimethyl phthalate, dioctyl phthalate, dibutyl sebacate, dimethyl sebacate, castor oil, glycerol monostearate, and coconut oil.

21. A device according to claim 1, wherein the first active agent is one of a biologically active agent, pharmacologically active agent, medicine, nutrient, food product, vitamin, insecticide, pesticide, herbicide, microbicide, algaecide, fungicide, grow regulating substance, parasiticide, sterilant, fertility promoter, biocide, rodenticide, disinfectant, plant growth promoter, preservative, fertility inhibitor, deodorant, catalysts, food supplement and cosmetic.

22. The device of claim 1, wherein the layer further comprises at least one of an osmagent and an osmopolymer; the expandable core further comprises at least one expandable hydrophilic polymer and, optionally, an osmagent.

23. The device of claim 22, wherein the membrane comprises about 1 to 99 weight percent of one or more cellulose esters, about 84 to 0.5 weight percent of one or more poly(methacrylate) copolymer salts and about 15 to 0.5 weight percent of one or more plasticizers.

24. The device of claim 23, wherein the expandable hydrophilic polymer

is one or more of hydroxypropyl methylcellulose, alkylcellulose, hydroxyalkylcellulose, poly(alkylene oxide), and combinations thereof; and the at least one cellulose ester is independently selected from the group consisting of cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate and combinations thereof.

25. The device of claim 23, wherein the at least one poly(methacrylate) copolymer salt is a poly(ammonium methacrylate) copolymer.

26. The device of claim 2, wherein the layer further comprises at least one of an osmagent and an osmopolymer; the expandable core further comprises at least one expandable hydrophilic polymer and, optionally, an osmagent.

27. The device of claim 26, wherein the membrane comprises about 1 to 99 weight percent of one or more cellulose esters, about 84 to 0.5 weight percent of one or more poly(methacrylate) copolymer salts and about 15 to 0.5 weight percent of one or more plasticizers.

28. The device of claim 27, wherein the expandable hydrophilic polymer is one or more of hydroxypropyl methylcellulose, alkylcellulose, hydroxyalkylcellulose, poly(alkylene oxide), and combinations thereof; and the at least one cellulose ester is independently selected from the group consisting of cellulose acylate, cellulose diacylate, cellulose triacylate, cellulose acetate, cellulose diacetate, cellulose triacetate and combinations thereof.

29. The device of claim 27, wherein the at least one poly(methacrylate) copolymer salt is a poly(ammonium methacrylate) copolymer.

30. A device for the controlled delivery of at least one active agent to an environment of use, wherein the device comprises: a core expandable in a fluid from the environment of use, the core being approximately centrally located in the device; a layer comprising at least one first active agent, wherein the layer is in contact with and surrounds the core; and a membrane in contact with and surrounding the layer and comprising one or more cellulose esters, one or more poly(methacrylate) copolymer salts and one or more plasticizers, wherein the membrane permits delivery of the at least one active substance through a combination of diffusion and osmotic pumping.

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 15307-86-5 REGISTRY



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CN Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Acetic acid, [o-(2,6-dichloroanilino)phenyl]- (8CI)
OTHER NAMES:
CN 2-(2,6-Dichloroanilino)phenylacetic acid
CN 2-(2,6-Dichlorophenylamino)phenylacetic acid
CN 2-[(2,6-Dichlorophenyl)amino]benzeneacetic acid
CN Dichlofenac
CN **Diclofenac**
CN Diclofenac acid
CN Diclomelan
CN Dicloreuma
CN N-(2,6-Dichlorophenyl)-o-aminophenylacetic acid
CN Pennsaid
CN Transfenac
CN [o-(2,6-Dichloroanilino)phenyl]acetic acid